Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 5
2006 1
2007 2
2008 2
2009 1
2010 4
2011 4
2012 4
2013 2
2014 1
2015 6
2016 6
2017 3
2018 3
2019 3
2020 6
2021 7
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martinez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, Cortés J, Braga S. Pérez-García JM, et al. Among authors: de la haba rodriguez j. Neuro Oncol. 2023 Jan 5;25(1):157-166. doi: 10.1093/neuonc/noac144. Neuro Oncol. 2023. PMID: 35639825 Free PMC article. Clinical Trial.
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P. Gianni L, et al. Among authors: de la haba rodriguez j. Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6. Lancet Oncol. 2012. PMID: 22153890 Clinical Trial.
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P. Gianni L, et al. Among authors: de la haba rodriguez j. Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11. Lancet Oncol. 2016. PMID: 27179402 Clinical Trial.
Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis.
Arpino G, de la Haba Rodríguez J, Ferrero JM, De Placido S, Osborne CK, Klingbiel D, Revelant V, Wohlfarth C, Poppe R, Rimawi MF; PERTAIN Study Group. Arpino G, et al. Among authors: de la haba rodriguez j. Clin Cancer Res. 2023 Apr 14;29(8):1468-1476. doi: 10.1158/1078-0432.CCR-22-1092. Clin Cancer Res. 2023. PMID: 36716289 Free PMC article. Clinical Trial.
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
Martin M, Zielinski C, Ruiz-Borrego M, Carrasco E, Turner N, Ciruelos EM, Muñoz M, Bermejo B, Margeli M, Anton A, Kahan Z, Csöszi T, Casas MI, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, de la Haba-Rodriguez J, Ramos M, Alvarez I, Garcia-Palomo A, Huang Bartlett C, Koehler M, Caballero R, Corsaro M, Huang X, Garcia-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M. Martin M, et al. Among authors: de la haba rodriguez j. Ann Oncol. 2021 Apr;32(4):488-499. doi: 10.1016/j.annonc.2020.12.013. Epub 2020 Dec 29. Ann Oncol. 2021. PMID: 33385521 Free article. Clinical Trial.
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial.
Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G; PERTAIN Study Group. Rimawi M, et al. Among authors: de la haba rodriguez j. J Clin Oncol. 2018 Oct 1;36(28):2826-2835. doi: 10.1200/JCO.2017.76.7863. Epub 2018 Aug 14. J Clin Oncol. 2018. PMID: 30106636 Clinical Trial.
The role of CDK4/6 inhibitors in early breast cancer.
Gil-Gil M, Alba E, Gavilá J, de la Haba-Rodríguez J, Ciruelos E, Tolosa P, Candini D, Llombart-Cussac A. Gil-Gil M, et al. Among authors: de la haba rodriguez j. Breast. 2021 Aug;58:160-169. doi: 10.1016/j.breast.2021.05.008. Epub 2021 May 25. Breast. 2021. PMID: 34087775 Free PMC article. Review.
Initialization of adjuvant hormonal treatment for breast cancer.
Martínez Guisado A, Sánchez Muñoz A, de la Cabeza Lomas Garrido M, Ruíz Borrego M, Bayo Calero J, de Toro Salas R, González Mancha R, de la Haba Rodríguez J, Alba Conejo E. Martínez Guisado A, et al. Among authors: de la haba rodriguez j. Adv Ther. 2011 Sep;28 Suppl 6:66-84. doi: 10.1007/s12325-011-0039-8. Epub 2011 Sep 16. Adv Ther. 2011. PMID: 21922396 Review.
Medication Non-Adherence in Rheumatology, Oncology and Cardiology: A Review of the Literature of Risk Factors and Potential Interventions.
Gil-Guillen VF, Balsa A, Bernárdez B, Valdés Y Llorca C, Márquez-Contreras E, de la Haba-Rodríguez J, Castellano JM, Gómez-Martínez J. Gil-Guillen VF, et al. Among authors: de la haba rodriguez j. Int J Environ Res Public Health. 2022 Sep 23;19(19):12036. doi: 10.3390/ijerph191912036. Int J Environ Res Public Health. 2022. PMID: 36231341 Free PMC article. Review.
Nitric oxide and cancer: the emerging role of S-nitrosylation.
Aranda E, López-Pedrera C, De La Haba-Rodriguez JR, Rodriguez-Ariza A. Aranda E, et al. Among authors: de la haba rodriguez jr. Curr Mol Med. 2012 Jan;12(1):50-67. doi: 10.2174/156652412798376099. Curr Mol Med. 2012. PMID: 22082481 Review.
65 results